2019 Ryan White HIV/AIDS Program CLINICAL CONFERENCE

Neisseriagonorrhoeae — PercentageofUrethral IsolateswithElevatedMinimum InhibitoryConcentrations(MICs)to Azithromycin*andCeftriaxone † bySexand Sexof SexPartners,Gonococcal IsolateSurveillanceProject(GISP),2009–2018

*Elevated Azithromycin MIC:≥2.0µg/mL. † Elevated Ceftriaxone MIC: ≥0.125 μg/mL.

CDC,2018 Surveillance Report

Slide43of47FromKAWorkowski,MDatNewOrleans, LA,December4-7,2019,RyanWhiteHIV/AIDSProgramCLINICALCONFERENCE, IAS  USA.

Gonorrhea

• Optimize therapeutic regimen • PK/PD, bacterial burden • Treatment Failures • Reinfection

• United States

• Ceftriaxone 250 mg IM in a single dose PLUS • Azithromycin 1 g orally in a single dose

• failure-culture/AST + partner treatment • Novel Agents (Zoliflodacin,Gepotidacin) • WGS for genomic epidemiology • identification ofmutations conferring resistance • Characterizing outbreaks and spread of resistant strains

• United Kingdom

• Ceftriaxone 1 gram IM in a single dose

• Europe (European CDC)

• Ceftriaxone 500mg IM in single dose PLUS • Azithromycin 2 gm orally in a single dose

• Japan

• Ceftriaxone 1 gm IV/IM in a single dose

Slide44of47FromKAWorkowski,MDatNewOrleans, LA,December4-7,2019,RyanWhiteHIV/AIDSProgramCLINICALCONFERENCE, IAS  USA.

GC Treatment Draft Recommendations

Ceftriaxone 500 mg IM once* *for persons weighing 150 kg or more, use 1g IM Ceftriaxone

Anti-chlamydial therapy when chlamydia has not been ruled out

• Azithromycin resistance is widespread and increasing • Wide inter-individual pharmacokinetics • Resistance prevention concentration unknown, likely higher than dose for cure • Pharyngeal gonorrhea is common/under-screened (test ofcure 7-10d)

Slide45of47FromKAWorkowski,MDatNewOrleans, LA,December4-7,2019,RyanWhiteHIV/AIDSProgramCLINICALCONFERENCE, IAS  USA.